Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.
Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses the next steps for the chimeric antigen receptor (CAR) T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 (NCT03548207) trial in patients with relapsed/refractory multiple myeloma.
The phase 2 portion of this study is now fully enrolled, says Berdeja. He is looking forward to combining data in this study with the findings from the phase 1b portion. The same dose from the initial study will be used in the phase 2. The purpose is to evaluate the durability of responses in this patient population, which have looked promising in the recently published data.
The FDA granted a Breakthrough Therapy Designation to JNJ-5428, and Berdeja hopes this will be a candidate for approval in the population of patients with relapsed/refractory multiple myeloma. Phase 2 and 3 studies are also underway looking at this CAR T product in earlier lines of therapy for patients with multiple myeloma, including the high-risk populations. The agent is even being evaluated as a frontline consolidation therapy in the myeloma landscape.
<< View more resources and information regarding multiple myeloma
Khouri Discusses Selinexor Dosing and Management Approaches for R/R MM
July 22nd 2024During a Case-Based Roundtable® event, Jack Khouri, MD, and participants discussed the use of selinexor with dose modifications to manage toxicity in patients with relapsed/refractory multiple myeloma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More